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Nine cases of cryptosporidiosis co-infections in AIDS patients were clinically categorised into severe (patients 1, 3,
8 and 9), moderate (patients 4 and 5) and mild (patients 2, 6 and 7). Formalin-fixed faecal specimens from these
patients were treated to obtain high quality DNA competent for amplification and sequencing of the 60-kDa
glycoprotein (GP60) gene. Sequence analysis revealed that one patient was infected with Cryptosporidium hominis
whereas the remaining eight patients were infected with C. parvum. Interestingly, the patients showing severe
cryptosporidiosis harboured two subtypes within the C. parvum allelic family IIc (IIcA5G3 and IIcA5G3R2),
whereas patients with moderate or mild infections showed various subtypes of the C. parvum allelic family IIa
(IIaA14G2R1, IIaA15G2R1, IIaA17G3R1 and IIaA18G3R1).
DNA extraction and genotyping of Cryptosporidium spp. is a challenging task on formalin-fixed stool samples,
whose diagnostic outcome is age-dependent. The method herein reported represents a step forward routine
diagnosis and improves epidemiology of HIV-related clinical cases. Due to the need to elucidate genetic richness of
Cryptosporidium human isolates, this approach represents a useful tool to correlate individual differences in
symptoms to subgenotyping lineages.
INTRODUCTION
Cryptosporidium spp. are oocysts-forming
Apicomplexan protozoa that cause a wide-
spread enteric infection (cryptosporidiosis)
in humans and animals, a disease which
results in sickness and severe diarrhoea. In
the immunocompetent host, the symptoms,
when present, last for about 2 weeks before
the infection is cleared (Riggs, 2002). Con-
versely, in high-risk host groups, particularly
neonates (Huang et al., 2004; Keating,
2005) or people with suppressed or deficient
immune systems (i.e. HIV/AIDS patients),
the infection can be severe, long-lasting and
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DOI: 10.1179/1364859411Y.0000000025even fatal (Amadi et al., 2002; Certad et al.,
2005). The vast majority of human cases of
cryptosporidiosis worldwide are caused by
two species, Cryptosporidium parvum and C.
hominis (Morgan et al., 1999). However,
other species, including C. felis, C. melea-
gridis, C. canis, C. suis, C. muris (Xiao and
Ryan, 2004) and, more rarely, C. cuniculus
(Robinson et al., 2010) and C. ubiquitum
(Fayer et al., 2010) can infect humans too,
especially children under the age of 5
years and immunocompromised individuals
(Abubakar et al., 2007).
The identification and characterization of
Cryptosporidium species and population variants
(genotypes and subgenotypes) is fundamental
to study the epidemiology of cryptosporidiosis,
being a valid support for prevention and control
strategies (Putignani and Menichella, 2010).
Oocyst morphology, host specificity or prefer-
ences in infection sites do not provide sufficient
information for the identification of Crypto-
sporidium species, genotypes or subgenotypes
(Fall et al., 2003; Jex and Gasser, 2010).
Advances in molecular technologies have led
to significant improvements in the characteriza-
tion of the genetic variability among and within
Cryptosporidium species (Jex and Gasser, 2008).
In particular, the amplification and sequencing
of one or more genetic loci (markers) have been
used for the categorization of Cryptosporidium
species, genotypes or subgenotypes (Xiao et al.,
2004; Chalmers et al., 2005; Plutzer and
Karanis, 2009; Bouzid et al., 2010). Mini- and
micro-satellites, or simple sequence repeats,
constitute a rich source of polymorphism and
have been extensively used for high-resolution
genotyping and mapping (Feng et al., 2000). In
particular, the GP60 gene is useful for such
studies as it contains multiple regions with high
mutation rates, including a ‘hyper-variable’
microsatellite region (Strong et al., 2000).
Herein we describe a successful retro-
spective subgenotyping of C. parvum and C.
hominis isolates, performed on aged forma-
lin-fixed stool samples from nine HIV-
infected patients, based on a combination
of optimized DNA extraction and sequence
analysis of a fragment of the GP60 gene.
Subgenotype lineages were correlated to
clinical manifestations for each patient.
The understanding of this relationship may
represent the starting point for further
extended studies on the correlation between
isolate type and symptom severity in HIV-
infected patients.
MATERIALS AND METHODS
Collection of Faecal Specimens and
Parasite Identification
Formalin-fixed stool samples were collected
from nine HIV-infected patients admitted to
the National Institute for Infectious Diseases
‘Lazzaro Spallanzani’ (Rome, Italy) between
2005 and 2006. The research protocol was
approved by the Institutional Review Board
of the Hospital. Participants had given
written informed consent before enrollment
into the study. Clinical data were provided
for each patient (Table 1).
Faecal samples were collected, fixed and
filtrated by using a 10% formalin disposable
system (Meridian Biosciences, Cincinnati,
OH, USA). Cryptosporidium oocysts were
detected by a modified Ziehl–Neelsen stain-
ing (Becton Dickinson, Franklin Lakes, NJ,
USA). After microscopic examination, the
residual stool aliquot was stored at 4uCi n
formalin before DNA extraction.
DNA Extraction from Formalin-fixed
Stools
DNA extraction was performed by the follow-
ing modification of the QIAamp DNA stool
mini kit (Qiagen, Hilden, Germany). Briefly,
200 ml of formalin-fixed stool samples were
washed three times with phosphate-buffered
saline (pH 7.4) and centrifuged to remove
traces of formalin before DNA extraction.
Samples were submitted to 15 freeze–thaw
cycles(freezing in liquid nitrogen for 1 minute
and heating at 65uC for 1 minute) and 1.4 ml
of ASL buffer (QIAamp DNA stool mini kit;
Qiagen) was added. The suspension was
mixed, incubated for 5 minutes at 95uCa n d
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CRYPTOSPORIDIOSIS CO-INFECTIONS IN AIDS PATIENTS 341processed according to the manufacturer’s
instructions (QIAamp DNA stool mini kit;
Q i a g e n ) .D N Aw a se l u t e di n5 0mlo fH 2O,
previously heated at 65uC for 15 minutes. As
positive control, DNA was extracted with the
same procedure from 10
7 Percoll purified
oocysts from the C. parvum isolate ISSC162,
subgenotype IIaA15G2, kindly provided by
the Department of Infectious, Parasitic and
Immunomediated Diseases (Istituto Superiore
di Sanita `, Rome, Italy).
GP60-based Subgenotyping
Af r a g m e n to ft h eGP60 gene was amplified
using a previously described nested-PCR pro-
tocol (Sulaiman et al., 2005). Both PCR
reactions, set up to a 25 mlv o l u m e ,w e r e
performed as previously described (Glaber-
man et al., 2002), except for the annealing
temperature (50 and 51uC, for first and second
rounds, respectively). An aliquot of 5 mlf r o m
the primary PCR reaction was used as template
in the secondary PCR reaction. Between
p r i m a r ya n ds e c o n d a r yP C R s ,ap u r i f i c a t i o n
step, performed by using a PCR clean-up
system (Wizard; Promega, Fitchburg, WI,
USA), was included to remove residual for-
malin affecting the secondary PCR. The
resulting DNA fragments, loaded on 2.2%
agarose gels (Sigma Aldrich, Milan, Italy), were
visualized by Gel Doc XR System and analysed
using the software Quantity One 4.6.3 (Bio-
Rad, Hercules, CA, USA). The size of the
amplified PCR products was estimated by
comparison with the Flash Gel 50 bp–1.5 kb
DNA ladder (Lonza, Rockland, ME, USA).
Sequencing reactions were performed by using
1.6 pmol of inner GP60 primers (Sulaiman
et al., 2005) and 1.5 ml of amplified DNA in a
final volume of 10 ml, hence cycled according
to the manufacturer (version 3.1; Applied
Biosystems, Foster City, CA, USA). Con-
sensus sequences corrected by base calling
were probed against non-redundant GenBank
databases using BLASTN algorithm (http://
www.ncbi.nlm.nih.gov/BLAST/). The highest
score matching was considered the most likely
correct identification, and only an identity
T
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to be considered significant. GP60 subgeno-
types were classified according to the nomen-
clature proposed by Sulaiman (Sulaiman et al.,
2005). Nucleotide sequences were deposited
into GenBank under accession nos. HM-
371366 to HM371374.
RESULTS
Clinical Manifestations of
Cryptosporidiosis
Cryptosporidium was identified in stools from
all nine patients, but in bronchoalveolar
lavage (BAL), sputum and duodenal biopsy
from three different patients. All patients
but one had CD4 counts less than 50 cell/ml
and a CDC C3, and were therefore suscep-
tible to severe cryptosporidiosis. None of the
subjects had suppressed HIV viraemia, with
viral load ranging from 1.938 to more than
500 000 cp/ml, mainly (8/9 patients) due to
poor compliance or failure of previous
HAART regimens. Eight out of the nine
Cryptosporidium cases were diagnosed be-
tween the moist months December and
March, and one in September. Diarrhoea
was complained of by all patients, and was
watery for 8 of 9. Weight loss was reported
by eight patients, with three of them
experiencing a strong weight loss (y15 kg
in 1 month) and four patients suffering from
wasting syndrome. Other common symp-
toms were: abdominal pain (7/9 patients),
fever and vomiting (6/9 patients), and
cough, often productive (4/9 patients);
however, Cryptosporidium was isolated from
sputum and BAL from only two patients.
One patient had frank pneumonia and
another had diffuse interstitial infiltrates.
Nutritional biomarkers were also altered.
Plasmatic albumin was low in 6/9 patients,
suggesting strong and lasting malabsorption.
As a consequence, the majority of patients
(5/9 patients) required the administration
of parenteral nutrition (PN) to contrast
clinical condition worsening. Chronic diar-
rhoea and malabsorption led to electrolyte
disturbances, especially hypokalaemia, ex-
cept for two patients. The fecal occult blood
resulted positive in six patients, but no
patient clearly showed haematic stools. For
patient 1, the histological examination of
duodenal biopsy revealed sphere shapes sug-
gestive of duodenal cryptosporidiosis. Also
the patient 9 had symptoms compatible with
biliary involvement, confirmed also by ima-
gining evidences, but neither endoscopic
retrograde cholecystopancreatography nor
biopsies of biliary ducts were performed to
certainly diagnose biliary cryptosporidiosis.
Candidiasis was a recurrent co-infection,
observed in 7/9 patients, mark of mucosal
changes or altered intestinal immunity. We
employed symptom features to categorize
patients into three different groups: severe,
moderate and mild cryptosporidiosis.
In the first set, patients 1, 3, 8 and 9 were
grouped (Table 1). Patient 1 was a hepatitis C
virus co-infected subject who presented with-
wasting syndrome, abdominal pain and
vomiting. During the hospitalization, an eso-
phagogastroduodenoscopy with biopsy was
performed and the histological examination
revealed a duodenal cryptosporidiosis (data
n o ts h o w n ) .S t o o le x a m i n a t i o nr e v e a l e d
the presence of Cryptosporidium oocysts
(Table 2). Treatment with metronidazole
and paromomycin failed with progressive
worsening of clinical conditions. However,
after a few days, the patient refused additional
therapies and was discharged against medical
advice (Table 1). Patient 3 presented with
mucocutaneous Kaposi’s sarcoma and wast-
ing syndrome. The patient was on HAART
failure. He presented with fever, diarrhoea,
dysphagia and weight loss. After hospitaliza-
tion PN, glucose, amino acids and electrolyte
solutions were started, but clinical conditions
progressively deteriorated and after 32 days of
hospital stay the patient died (Table 1).
Patient 8 was a hepatitis C virus co-infected
subject presenting with wasting syndrome and
atypical mycobacteriosis who began both
HAART and antimycobacterial therapy,
with further improvement and discharge
(Table 1). Patient 9 presented with wasting
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CMV infection with recurrent symptoms of
diarrhoea and vomiting. Multiple HAART
regimens were undertaken but failed. During
hospitalization, he presented abdominal pain
with marked elevations of amylases, lipases and
cholestatic indexes. Abdominal ultrasound and
magnetic resonance cholangiography showed
intra- and extrahepatic dilatation of the biliary
tree, edematous pancreas and a gallbladder
filled with dense bile (suggesting duodenal
cryptosporidiosis), but a duodenal biopsy was
not undertaken. A chest X-ray evidenced
diffuse interstitial infiltrates and pleural effu-
sion. Sputum (data not shown) and stool
examinations revealed Cryptosporidium oocysts
(Table 2). His clinical conditions progressively
worsened and he died.
The second set (moderate symptoms)
included patients 4 and 5 (Table 1). Patient
4 complained lack of appetite and had
diarrhoea for about 2 months. Due to diar-
rhoea persistence, patient underwent a recto-
sigmoidoscopy suggesting ulcerative colitis;
hence, a therapy with mesalazine and metro-
nidazole was begun. Despite the therapy, the
diarrhoea persisted and the patient began to
additionally present productive cough and
fever. A chest X-ray showed an interstitial
reticulonodular pattern with a basal parench-
ymal consolidation (Table 1). Pulmonary
tuberculosis was suspected but the BAL
revealed the presence of Cryptosporidium
oocysts (data not shown), also detected in
large amounts in the stools (Table 2). Patient
received PN, antibiotic therapy (paromomy-
cin/azithromycin) and HAART with progres-
sive improvement and further discharge.
Patient 5 was admitted presenting fever, ab-
dominal pain, diarrhoea and ingravescent loss
of weight. Therefore, HAART was begun.
Stool examination showed numerous Cryptos-
poridium oocysts (Table 2) and a therapy with
paromomycin/azithromycin was hence admini-
strated. Afterwards, the clinical manifestations
ameliorated and the patient was discharged.
The third set (mild symptoms) included
patients 2, 6 and 7. Patient 2 complained
watery diarrhoea, abdominal pain and loss
of weight for 2 months and productive
cough for 1 month. Stool examinations
revealed Cryptosporidium oocysts (Table 2).
HAART was not started; however, ameli-
oration of clinical conditions was observed
leading to his discharge. Patient 6 com-
plained fever, watery diarrhoea, abdominal
pain and dysphagia. Stool examinations
revealed Cryptosporidium oocysts (Table 2).
After a few days, diarrhoea diminished and
the patient was discharged against medical
advice. For patient 7, the seropositivity
status was unknown on admission. He
presented diarrhoea, dyspepsia and progres-
sive loss of weight. Rifaximin was adminis-
tered without any improvement; hence, the
patient was hospitalized and therefore tested
HIV-seropositive. Stool examination was
positive for both Ascaris lumbricoides and
Cryptosporidium (Table 2). Diarrhoea per-
sisted despite the use of albendazole, but
was reduced after paromomycin/azithro-
mycin administration, leading to patient
discharge.
DNA Extraction and Amplification
from Formalin-fixed Stools
The optimization of the DNA extraction
step from aged formalin-fixed stools was
based on repeated phosphate-buffered sal-
ine washings for formalin excess removal
followed by a thermal stress-induced rup-
ture of oocysts for DNA release, by repeated
freeze/thaw cycles and heating of the sam-
ples at 95uC. Mechanical oocyst disruption
was not associated to an improved DNA
yield and competence for amplification
(data not shown). DNA competence was
improved by choosing a small size DNA
target (358 bp), thus minimizing the effect
of formalin-induced DNA fragmentation.
GP60-based Subgenotyping
Nested-PCR at the GP60 locus yielded single
products of the expected size for all samples.
All products were successfully sequenced.
BLAST analysis revealed that four isolates
344 DEL CHIERICO ET AL.(samples 1, 3, 8 and 9) belonged to the C.
parvum allelic family IIc: precisely, three
samples (1, 3 and 8) were classified as subge-
notype IIcA5G3 and one sample (9) as
IIcA5G3R2 (Table 2). Four isolates, belong-
ing to the allelic family IIa, were classified as
IIaA18G3R1 (sample 2), IIaA15G2R1 (sam-
ple 4), IIaA17G3R1 (sample 5) and IIaA14-
G2R1a (sample 7) (Table 2). A single isolate
(sample 6) belonged to the C. hominis sub-
genotype IaA12G1 (Table 2).
DISCUSSION
Based on symptom features, we catego-
rized patients into three different groups:
severe, moderate and mild cryptosporidiosis
(Table 1). Consistently, the GP60 subgeno-
typing was discussed for the three patient
sets. GP60 subgenotyping, for the first group
of patients, identified only the IIcA5G3
lineage, while for the other two groups, a
wider variety of lineages was reported. The
C. parvum allelic family IIc has been fre-
quently recorded (Jex and Gasser, 2010) and
described from at least 12 countries:
Australia (Jex et al., 2007; Jex et al., 2008;
O’Brien et al., 2008), Guatemala (Peng et al.,
2001), Japan (Abe et al., 2006), Kuwait
(Sulaiman et al., 2005), Malawi (Peng et al.,
2003), Peru ` (Cama et al., 2008), Portugal
(Peng et al., 2001; Alves et al., 2006), South
Africa (Leav et al., 2002), Spain (Jex and
Gasser, 2008), The Netherlands (Wielinga
et al., 2008), Slovenia (Soba and Logar,
2008) and Uganda (Akiyoshi et al., 2006).
However, to date, this allelic family has been
recorded almost exclusively in humans (Xiao
and Feng, 2008; Bouzid et al., 2010) and
only recently in hedgehogs (Dyachenko et al.,
2010). Based on the clinical evidence, wast-
ing syndrome appears strongly linked to
infection with parasite of the family IIc (4/4
patients), whereas no wasting syndrome was
observed in patients infected with Ia and IIa
families (Table 1). Remarkably, for 2/4
IIcA5G3 patients (1 and 9), esophagogas-
troduodenoscopy and magnetic resonance
cholangiography exams suggested an ex-
tended and atypical colonization (Lumadue
et al., 1998) of the subtype IIcA5G3 to other
sites (bile-duct/duodenum tract), different
from sigmoid colon and rectum (Vela ´squez
et al., 2010). The infection of the biliary tree
represents a reservoir from which intestinal
cryptosporidiosis may relapse and allows
the organism to avoid luminal antiparasitic
agents such as paromomycin (Chalmers and
Davies, 2010). In these cases, drugs like
nitaxozanide with biliary excretion should be
used (Baishanbo et al., 2006). Indeed, the
administration of paromomycin, even if
integrated by metronidazole, failed as speci-
fic treatment of cryptosporidiosis (Palmieri
et al., 2005; Pozio and Morales, 2005) for
patient 1. For the second patient set (4 and
5), subtypes IIaA15G2R1 and IIaA17G3R1
were observed. The IIa allelic family com-
prises some 50 subgenotypes, has been
detected in 26 countries worldwide, includ-
ing Italy, with a prevalence of 25.5% in
humans and of 57.8% in all other hosts (Jex
andGasser,2010),andhas been described as
theonly orprevalent familyinsome extended
geographical areas (Plutzer and Karanis,
2007). The IIaA15G2R1 subtype, preva-
lently reported from farm animals, has
zoonotic potential (Jex and Gasser, 2010).
However, IIaA15G2R1 has been detected in
human samples from Australia (O’Brien
et al., 2008) and from sporadic human cases
in Portugal (Alves et al., 2003), Belgium
(Geurden et al., 2009), Ireland (Zintl et al.,
2009), Kuwait (Sulaiman et al., 2005),
Canada (Trotz-Williams et al., 2006), Japan
(Amer et al., 2010) and the USA (Peng et al.,
2003). Remarkably, this subtype was also
linkedtoanoutbreakassociatedwith anopen
farm in Wales (UK) (Chalmers et al., 2005),
supporting a zoonotic transmission. The
other subtype IIaA17G3R1 was described
both in calves and humans in Northern
Ireland (Glaberman et al., 2002; Thompson
et al., 2007), and in humans in Australia
(Waldron et al., 2009).
Interestingly, an extra-intestinal cryptos-
poridiosis was noted for patients 4, similarly
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receiving PN, the paromomycin/azithromy-
cin combined therapy gradually improved
the clinical conditions leading to patient
discharge. The same symptoms were also
seen in patient 5, despite the absence of
pulmonary involvement. Only stool exam-
ination showed numerous Cryptosporidium
oocysts; the same antibiotic therapy, used
for patient 4, induced amelioration of her
clinical manifestations.
For the third set of patients (2, 6 and 7),
subtypes IIaA18G3R1, IIaA14G2R1a and
IaA12G1 were observed. The first subtype
h a sb e e nv e r yc o m m o n l yr e p o r t e di nh u m a n s
and cattle in Ireland (Zintl et al., 2009) and
Australia (Waldron et al.,2 0 0 9 ) ,a n di n
p a t i e n t2 ,i ts e l f -resolved upon patient’s
discharge. To the best of our knowledge,
the IIaA14G2R1a subtype (Table 2), char-
acterized in Germany for the first time by
Broglia et al. (2008) in cattle, is herein re-
ported as a novel human subtype (patient 7).
An important co-infection with A. lumbri-
coides was observed for this patient, but only
a specific anti-Cryptosporidium treatment
resolved diarrhoea. Interestingly, only for
patient 6, a C. hominis subtype (IaA12G1)
was reported. The allelic family Ia has a
worldwide distribution and is significantly
diverse at the subtype level (25 subtypes
reported; Jex and Gasser, 2010). There may
be slight differences in the clinical manifesta-
tions depending on C. hominis subtypes, as
previously described (Cama et al., 2007).
Apparently, the C. hominis infection for
patient 6 was associated with the absence of
fecal occult blood and required PN; there
was no wasting syndrome and his weight loss
was not remarkable when compared to the
other patients.
Fixatives are essential for preservation of
stool specimens. Buffered formalin is a tradi-
tional stool fixative, still considered the ‘gold
standard’ in parasitology by virtue of its
excellent long term preservative activity on
intestinal parasites. However, the extraction of
high-quality genomic DNA and its amplifica-
tion is usually hampered by the high nucleic
acid fragmentation chemically induced and by
the presence of remnants of formalin that
inhibit the amplification reaction. Because of
TABLE . Conventional diagnosis and molecular typing of Cryptosporidium spp. isolates from stool samples
Patient/sample code
Microscopy-based diagnosis
Species
Subgenotyping
No. of oocysts/field Image (61000) GP60 GenBank Accession
15 C. parvum IIcA5G3 HM371366
23 C. parvum IIaA18G3R1 HM371367
31 C. parvum IIcA5G3 HM371368
4 120 C. parvum IIaA15G2R1 HM371369
51 0 C. parvum IIaA17G3R1 HM371370
61 C. hominis IaA12G1 HM371371
71 C. parvum IIaA14G2R1a HM371372
85 C. parvum IIcA5G3 HM371373
91 C. parvum IIcA5G3R2 HM371374
Dark and pale grey apply to sets of patients referred as affected by severe and moderate cryptosporidiosis,
respectively.
TABLE 2.
346 DEL CHIERICO ET AL.these difficulties, we have developed a new
protocol that yields DNA suitable for ampli-
fication of small size targets, which are
less affected by sporadic DNA breakages.
Cryptosporidium DNA extraction was per-
formed directly from stool samples, without
prior oocyst purification or concentration
steps. The method relies on a chemical lysis
sustained by a heating effect acting at two
protocol stages before lysis and spin-column
steps. However, no mechanical oocyst disrup-
tion, based on additional required equipments,
was introduced to enhance the DNA yield, as
previously reported (Zhu et al., 1998). The
heating disruption appeared a resolutive deter-
minant in the breakage of formalinized oocysts/
sporozoites and in the release of amplifiable
DNA. The protocol was introduced as a
convenient bench-side procedure for stool
specimen analysis and it was employed to
select appropriate subgenotyping markers and
to link subgenotyping lineages to individual
manifestations of cryptosporidiosis.
Cryptosporidium subgenotyping is an impor-
tant tool for the understanding its population
structure. Given the need to investigate the
genetic diversity of Cryptosporidium clinical
isolates, still underestimated for technical
difficulties to handle formalin-fixed stools, the
method herein described may offer advantages
for routine diagnosis and clinical epidemiolo-
gical studies, despite referring to a small-scale
patient dataset. Therefore, further evidence
from larger sample size appears necessary to
prove a statistically significant correlation be-
tween symptom severity and genotype. The
interactionship may therefore provide insights
on subgenotype lineages and HIV-associated
cryptosporidiosis to unveil, on large patient
cohorts, determinants of clinical diversity of
cryptosporidiosis associated with genetic com-
plexity of the parasite.
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